Evidence map›Paper›PMID 23139603›Full record

Trial reportWorld journal of gastroenterology2012

Several factors including ITPA polymorphism influence ribavirin-induced anemia in chronic hepatitis C.

Akihito Tsubota, Noritomo Shimada, Hiroshi Abe, Kai Yoshizawa, Rie Agata, Yoko Yumoto, Makiko Ika, Yoshihisa Namiki, Keisuke Nagatsuma, Hiroshi Matsudaira and 3 more

Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in World journal of gastroenterology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Role of ITPA gene polymorphism in ribavirin-induced anemia and thrombocytopenia in Egyptian patients with chronic hepatitis C.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2016
    Article
  4. Article
  5. Article
  6. Personalized medicine and the clinical laboratory.Einstein (Sao Paulo, Brazil) · 2014
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Akihito TsubotaInstitute of Clinical Medicine and Research, The Jikei University School of Medicine, 163-1 Kashiwa-shita, Kashiwa, Chiba 277-8567, Japan. atsubo@jikei.ac.jp
Noritomo Shimada
Hiroshi Abe
Kai Yoshizawa
Rie Agata
Yoko Yumoto
Makiko Ika
Yoshihisa Namiki
Keisuke Nagatsuma
Hiroshi Matsudaira
Kiyotaka Fujise
Norio Tada
Yoshio Aizawa
Jikei University Kashiwa hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo construct formulae for predicting the likelihood of ribavirin-induced anemia in pegylated interferon α plus ribavirin for chronic hepatitis C.

methodsFive hundred and sixty-one Japanese patients with hepatitis C virus genotype 1b who had received combination treatment were enrolled and assigned randomly to the derivation and confirmatory groups. Single nucleotide polymorphisms at or nearby ITPA were genotyped by real-time detection polymerase chain reaction. Factors influencing significant anemia (hemoglobin concentration < 10.0 g/dL at week 4 of treatment) and significant hemoglobin decline (declining concentrations > 3.0 g/dL at week 4) were analyzed using multiple regression analyses. Prediction formulae were constructed by significantly independent factors.

resultsMultivariate analysis for the derivation group identified four independent factors associated with significant hemoglobin decline: hemoglobin decline at week 2 [P = 3.29 × 10(-17), odds ratio (OR) = 7.54 (g/dL)], estimated glomerular filtration rate [P = 2.16 × 10(-4), OR = 0.962 (mL/min/1.73 m(2))], rs1127354 (P = 5.75 × 10(-4), OR = 10.94) and baseline hemoglobin [P = 7.86 × 10(-4), OR = 1.50 (g/dL)]. Using the model constructed by these factors, positive and negative predictive values and predictive accuracy were 79.8%, 88.8% and 86.2%, respectively. For the confirmatory group, they were 83.3%, 91.0% and 88.3%. These factors were closely correlated with significant anemia. However, the model could not be constructed, because no patients with rs1127354 minor genotype CA/AA had significant anemia.

conclusionReliable formulae for predicting the likelihood of ribavirin-induced anemia were constructed. Such modeling may be useful in developing individual tailoring and optimization of ribavirin dosage.

Indexed as

Polymorphism, Single NucleotideAgedAnemiaAntiviral AgentsBiomarkersChi-Square DistributionDrug Therapy, CombinationFemaleGenetic Predisposition to DiseaseHemoglobinsHepatitis C, ChronicHumansInosine TriphosphataseInterferon-alphaInterferon alpha-2JapanAntiviral AgentsBiomarkersHemoglobinsInosine TriphosphataseInterferon-alphaInterferon alpha-2ITPA protein, humanpeginterferon alfa-2apeginterferon alfa-2bPolyethylene GlycolsPyrophosphatasesRecombinant ProteinsRibavirinChronic hepatitis C virus infectionHemolytic anemiaPegylated interferon αPrediction modelRibavirinSingle nucleotide polymorphism

Identifiers

PMID23139603
PMCPMC3491594
OpenAlexW2135241019

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.